Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 11, 2022 Poster

2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies

2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies: View Poster
December 11, 2022 Poster

2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes

2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: View Poster
August 19, 2022 Presentation

Aptose Corporate Presentation August 2022

Aptose Corporate Presentation August 2022: View Presentation
July 19, 2022 Presentation

Aptose Corporate Presentation July 2022

Aptose Corporate Presentation July 2022: View Presentation
June 27, 2022 Presentation

Aptose Corporate Presentation June 2022

Aptose Corporate Presentation June 2022: View Presentation
June 10, 2022 Poster

2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models

2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models: View Poster
June 2, 2022 Presentation

Aptose KOL Event and Clinical Update

Aptose KOL Event and Clinical Update: View Presentation
March 15, 2022 Presentation

Aptose Corporate Presentation March 2022

Aptose Corporate Presentation March 2022: View Presentation
December 13, 2021 Presentation

Aptose Corporate Update at ASH 2021

Aptose Corporate Update at ASH 2021: View Presentation